Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results